James Han, MD
Gastroenterology · Las Vegas, NVNPI 1144675414
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,095 of the $47,135 with a category attached, or 74.5%. AbbVie accounts for 82.3% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $37,064, more than ten times the $856 reported in 2021. Among gastroenterology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $137.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$39K
- Phathom Pharmaceuticals, Inc.$3K
- Johnson & Johnson$929
- Conmed Corporation$537
- Sanofi$533
- Boston Scientific$315
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$35,09574%
- Travel & lodging$1,6193%
- Food & beverage$10,14622%
- Education$2551%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 166 | $38,786 |
| Phathom Pharmaceuticals, Inc. | 7 | $3,204 |
| Johnson & Johnson | 39 | $929 |
| Conmed Corporation | 4 | $537 |
| Sanofi | 29 | $533 |
| Boston Scientific | 2 | $315 |
| Regeneron Healthcare Solutions, Inc. | 8 | $294 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $285 |
| Janssen Scientific Affairs, LLC | 2 | $256 |
| Pfizer | 9 | $241 |
| Gilead | 7 | $191 |
| Ardelyx, Inc. | 14 | $149 |
| Nestle Healthcare Nutrition Inc. | 3 | $147 |
| Medtronic | 1 | $130 |
| Lilly USA, LLC | 3 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| Ironwood Pharmaceuticals, Inc | 6 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $84 |
| Braintree Laboratories, Inc. | 4 | $73 |
| Celltrion USA Inc. | 3 | $72 |
| Intercept Pharmaceuticals, Inc. | 4 | $71 |
| Inspire Medical Systems, Inc. | 2 | $70 |
| Intra-sana Laboratories | 1 | $50 |
| Novo Nordisk | 3 | $50 |
| Ferring Pharmaceuticals Inc. | 2 | $37 |
| Aimmune Therapeutics, Inc. | 1 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Redhill Biopharma Inc. | 2 | $34 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Exact Sciences | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Orphalan Inc | 1 | $24 |
| Echosens North America, Inc. | 1 | $17 |
| Capsovision, Inc. | 1 | $16 |
| Digestive Care, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$20,478
- Rinvoq$15,696
- VOQUEZNA$3,162
- STELARA$405
- CONMED HEMOSTASIS$282
- Tremfya$250
- DUPIXENT$248
- EXALT Model D$140
- CONMED BILIARY$139
- GI Genius$130
- ZENPEP$125
- Creon$124
- ZEPOSIA$120
- TRULANCE$116
How this compares
$47,135 in reported general payments places this provider in the 95th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 11 | $97,598 |
| LinzessLinaclotide | 23 | $23,245 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 48 | $8,211 |
| Mesalamine | 12 | $6,287 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 16 | $2,546 |
| Pantoprazole Sodium | 185 | $1,581 |
| Famotidine | 164 | $1,375 |
| Omeprazole | 206 | $1,365 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 73 | $1,235 |
| Dicyclomine Hcl | 61 | $1,037 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 67 | $878 |
| Ondansetron OdtOndansetron | 30 | $724 |
| Sodium Chloride0.9 % Sodium Chloride | 40 | $598 |
| Hydrocortisone | 48 | $544 |
| LoperamideLoperamide Hcl | 18 | $418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $38,786 | $120,84334 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $37 | $8,21148 claims |
| Braintree Laboratories, Inc.Sutab | $73 | $2,54616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Las Vegas
- Christian StoneLas Vegas$1.1M
- Filippo CremoniniLas Vegas$36K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- David ShihLas Vegas$26K
- Noel FajardoLas Vegas$22K
- Frank FarisLas Vegas$14K
- Tarek AmmarLas Vegas$14K
- Eladio CarreraLas Vegas$13K
- Uday SaraiyaLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.